BeaglePlay® From BeagleBoard.org® Brings Fun to Building With Computers
8.3.2023 15:00:00 CET | Business Wire | Press Release
The BeagleBoard.org® Foundation today announces the global availability of BeaglePlay®, the most adaptable open-source performance platform available. Built on our proven open source Linux approach, BeaglePlay® has a feature set that includes built-in wired and wireless connectivity and ability to connect to a wide selection of sensor and prototyping systems with thousands of options, as well as interfaces and processing performance to support them.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005088/en/
BeaglePlay enables connections that make computing fun. (Photo: Business Wire)
Details at www.beagleplay.org.
Leveraging the Texas Instruments AM625 processor with quad 64-bit Arm® Cortex®-A53 cores, low-latency microcontroller subsystems, a dedicated Texas Instruments SimpleLink™ CC1352P7 sub-1 GHz and 2.4-GHz wireless MCU, and a Texas Instruments WiLink™ WL1807MOD Wi-Fi® module, new and experienced users can use a wide variety of application libraries and examples from Linux, Zephyr, MicroPython and numerous other open source frameworks to add an endless array of sensors, actuators, indicators and new connectivity options.
BeaglePlay® software features a customized BeagleBoard.org® Debian Linux image with desktop pre-installed along with features such as Wi-Fi® access point and BeagleConnect® gateway functionality supporting quick and flexible development options.
Build the broadest range of performance applications, including:
- Industrial Human Machine Interface (HMI)
- Retail and POS Automation
- 3D Point Cloud Systems
- Vision Analytics
- Vehicle and Drone Infrastructure
- 3D Reconfigurable Display Systems
- Medical Equipment
- Smart Buildings and Edge AI
- web3 Distributed Infrastructure
BeaglePlay® feature set enables connectivity to the widest selection of sensor and prototyping systems as well as interfaces with memory and processing performance in a low-cost solution:
Expandability
- MikroBus header giving access to hundreds of existing Click sensors and actuators
- Grove connector, by SEEED Studio, a rich, standardized prototyping ecosystem
- SparkFun QWIIC Connect interface provides access to sensors, LCDs, relays and more
Memory
- 2GB (1Gbx16) 1600MHz 3200 Mbps DDR4
- 16GB eMMC flash with high-speed interface
- MicroSD card slot
Interfaces
- Wi-Fi® / 2.4G, MIMO/5G, SISO via TI WiLink™ 8 WL1807 module
- Bluetooth® Low-Energy (BLE)/SubG via TI CC1352P7 M4+M0 with BeagleConnect® firmware
- HS-USB Type-C interface for power input and data
- HS-USB Type-A interface
- Gigabit Ethernet with RJ45
- 10Mbit single pair Ethernet (SPE) and 5V/250mA power over data line (PoDL) with RJ11
Display and Camera Connectors
- HDMI Type-A supporting up to Full-HD/1080P with 24-bit RGB
- FPC 22 pin 4-Lane MIPI CSI camera connector
- FPC 40 pin OLDI (LVDS) display interface
User Interfaces
- 1* User Programmable button, 1* Reset button, 1* Power button
- 1* Power indication LED, 5* User LEDs
- 4* U.FL Antenna connectors
- 2* JTAG 10pin TAG-CONNECT pads for debug connection
- Real Time Clock (RTC) Circuitry with coin cell battery backup
AM6254 Quad 64-bit Arm® Cortex®-A53, 1.4 GHz processor subsystem featuring:
-
Quad-core Cortex-A53® cluster with
- 512KB L2 shared cache
- Each Core with 32KB L1 DCache and 32KB L1 ICache
- Single-core Arm® Cortex®-M4F at up to 400 MHz
- Single-core Arm® Cortex®-R5F
- 3D GPU; up to 2048x1080 @60fps, OpenGL ES 3.1, Vulkan 1.2
-
Programmable Real-Time Unit Subsystem
- Dual-core PRUSS running at 333MHz
- Tightly integrated and offering low-latency control of IO pins
- Take advantage of BeagleBoard.org and other community software libraries
"BeaglePlay® is an exciting addition to the BeagleBoard.org® family and will enable thousands of applications to be prototyped faster than ever before.” stated Christine Long, CEO of the BeagleBoard.org® Foundation. “At this extremely competitive price point and ease of use, more developers’ work becomes like play!”
For additional information and distributor links to purchase, visit https://beagleplay.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005088/en/
Contact information
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom